Brought to you by 
Vantia brings in £19mm with its Series A venture round
07 Sep 2011
Executive Summary
Vantia (spin-off of Ferring Pharmaceuticals AS; urological and gynecological conditions) has raised £19mm ($38.4mm) through its Series A venture round from a group of investors, including lead backer MVM Life Science Partners, SV Life Sciences, and Novo AS.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vantia brings in £19mm with its Series A venture round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice